Measured lipid changes, an ongoing Lp(a) priority and three differently defined ageing measures. This case keeps the detail visible so each result can be read in context.
Over approximately six months, S.H.’s ApoB fell from 89 to 73 mg/dL and homocysteine from 14.6 to 9.6 µmol/L. LDL-C fell from 118 to 95 mg/dL, hs-CRP from 1.31 to 0.73 mg/L and Lp(a) from 64.7 to 51.4 mg/dL. Her case also records three ageing measures, each with its own interpretation.
Understand what each measure actually reports
S.H.’s record places lipid and homocysteine changes alongside approximate PhenoAge and GrimAge estimates and a DunedinPACE reading. Labelling those measures separately helps readers understand the comparison, while keeping the remaining Lp(a) priority in view.
Starting point and context
PhenoAge is supplied as an estimate of approximately 30 to 28 years and GrimAge as approximately 40.5 to 38.5 years. DunedinPACE is reported at 1.05 then 0.95. DunedinPACE is a pace-of-ageing measure, not an age in years.
Explore EVA blood biomarker testing
The recorded results
| Biomarker | Baseline | 6-Month Review | Change |
|---|---|---|---|
| Cardiovascular & Lipids | |||
| ApoB (mg/dL) | 89 | 73 | −18% |
| LDL-C (mg/dL) | 118 | 95 | −19% |
| Non-HDL (mg/dL) | 130.1 | 111.4 | −14% |
| HDL-C (mg/dL) | 64.9 | 68.6 | +6% |
| Lp(a) (mg/dL) | 64.7 | 51.4 | −21% |
| Inflammation & Methylation | |||
| hs-CRP (mg/L) | 1.31 | 0.73 | −44% |
| Homocysteine (µmol/L) | 14.6 | 9.6 | −34% |
| Biological Age | |||
| PhenoAge (estimated) | ~30 yrs | ~28 yrs | −2 yrs |
| GrimAge (estimated) | ~40.5 yrs | ~38.5 yrs | −2 yrs |
| DunedinPACE | 1.05 | 0.95 | −10% |
Figures are reproduced from the case record, including qualitative entries and reported percentage changes. Source labels such as optimal describe the case’s interpretation, not a universal reference range. A dash indicates a value not supplied.
Context that matters
- The source provides approximately six months of follow-up but no calendar dates or chronological age. These details have not been inferred.
- The DunedinPACE change from 1.05 to 0.95 is an approximately 10% reduction relative to baseline. It does not prove a sustained change over decades or an additional decade of healthy lifespan.
- S.H.’s Lp(a) values use mg/dL, unlike several other cases using nmol/L.
- Lp(a) remained above the source’s stated target below 30 mg/dL. A further protocol phase and a coronary calcium CT scan were planned in the source; no later result is supplied.
The recorded protocol
The following items are recorded in this person’s plan. This is a historical description, not a protocol for readers to copy.
- Omega-3 EPA/DHA (ApoB, CRP)
- Inulin prebiotic (LDL reduction via gut-liver)
- B6 + L-Methylfolate + Methylcobalamin B12 (homocysteine)
- Niacinamide (homocysteine, Lp(a) nudge)
- L-Carnitine (Lp(a) reduction support)
- Antioxidant and mineral support stack
Learn about personalised supplements
What remained in progress
Lp(a) remained a cardiovascular focus despite the lower reading. The case records an oral supplement plan and further monitoring. Observing several changes in the same direction is useful clinical context, but it does not establish that the supplement plan caused every change or quantify future disease prevention.
Reading the biological-age result
Biological-age scores are model outputs derived from the inputs available to that model. A lower score is not a measured gain in lifespan. Different models use different inputs and should be labelled and interpreted separately.
Are all three ageing measures ages in years?
No. PhenoAge and GrimAge are shown here as approximate age estimates. DunedinPACE is a pace measure reported as 1.05 and 0.95. These different measures should not be combined into a single age reduction.
How this connects to EVA
EVA connects blood testing, clinician-reviewed personalised supplements and follow-up. Blood Intelligence uses your blood results; Elite DNA + Blood adds genetic information. DNA is optional. The aim is a personal plan grounded in your information, with review as new results become available.
Put your numbers into a clearer context
If several markers or ageing measures are competing for your attention, start with a review that connects the results to your individual context.
See how to start with EVAExplore blood testing, optional DNA and personalised supplements, with the current steps to get started in Dubai.
This is an individual observational case, not a controlled trial. Biomarker changes and biological-age scores do not establish the effect of a particular supplement, predict an individual’s lifespan or guarantee future results. The protocol described was personalised and is not a recommendation to self-prescribe. EVA supports informed health decisions and is not intended to diagnose, treat, cure or prevent disease. Consult a qualified healthcare provider for medical advice.
Source: EVA clinical case record supplied for publication. Observation dates and model names are shown in the case. Prepared for web publication in October 2026.